# Effect of Finerenone on Myocardial Fibrosis and Cardiac Function in HFmrEF/HFpEF Patients

Study · id `cardio:ct-nct07583173` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07583173](<https://clinicaltrials.gov/study/NCT07583173>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07583173

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 104 participants.

## Technical summary

Registry record NCT07583173. Randomized; triple masking; primary purpose treatment. Start 2026-05-15 (anticipated); primary completion 2027-10-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 104 participants (planned count; ClinicalTrials.gov record NCT07583173, source copy `cardio:ctgov-nct07583173-2026-05-13`, retrieved 2026-10-26)
- Planned start: 2026-05-15 (anticipated) (ClinicalTrials.gov record NCT07583173, source copy `cardio:ctgov-nct07583173-2026-05-13`, retrieved 2026-10-26)
- Primary completion: 2027-10-31 (anticipated) (ClinicalTrials.gov record NCT07583173, source copy `cardio:ctgov-nct07583173-2026-05-13`, retrieved 2026-10-26)
- Completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT07583173, source copy `cardio:ctgov-nct07583173-2026-05-13`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07583173, source copy `cardio:ctgov-nct07583173-2026-05-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07583173-2026-05-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Finerenone on Myocardial Fibrosis and Cardiac Function in HFmrEF/HFpEF Patients
- Acronym: FINE-FOCUS
- Condition: Heart Failure
- Intervention (Drug): Oral finerenone
- Intervention (Drug): Placebo
- Lead sponsor: China National Center for Cardiovascular Diseases
- Lead sponsor class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Finerenone (`cardio:finerenone`)
- Registry intervention is a member of this class by a sourced record link: Mineralocorticoid receptor antagonists (drug class) (`cardio:mineralocorticoid-receptor-antagonists`)
- Registry lists this organization as the lead sponsor: China National Center for Cardiovascular Diseases (`cardio:org-china-national-center-for-cardiovascular-diseases`)

## Provenance

Content hash: cb37fb98c4804f3a03e8de6f9eae91b8ef7517c4c494a867698d14d4226d3cf8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
